Literature DB >> 26388264

Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

Claire Y Zhao1, Joseph L Greenstein2, Raimond L Winslow3.   

Abstract

In cardiac myocytes, the second messenger cAMP is synthesized within the β-adrenergic signaling pathway upon sympathetic activation. It activates Protein Kinase A (PKA) mediated phosphorylation of multiple target proteins that are functionally critical to cardiac contractility. The dynamics of cAMP are also controlled indirectly by cGMP-mediated regulation of phosphodiesterase isoenzymes (PDEs). The nature of the interactions between cGMP and the PDEs, as well as between PDE isoforms, and how these ultimately transduce the cGMP signal to regulate cAMP remains unclear. To better understand this, we have developed mechanistically detailed models of PDEs 1-4, the primary cAMP-hydrolyzing PDEs in cardiac myocytes, and integrated them into a model of the β-adrenergic signaling pathway. The PDE models are based on experimental studies performed on purified PDEs which have demonstrated that cAMP and cGMP bind competitively to the cyclic nucleotide (cN)-binding domains of PDEs 1, 2, and 3, while PDE4 regulation occurs via PKA-mediated phosphorylation. Individual PDE models reproduce experimentally measured cAMP hydrolysis rates with dose-dependent cGMP regulation. The fully integrated model replicates experimentally observed whole-cell cAMP activation-response relationships and temporal dynamics upon varying degrees of β-adrenergic stimulation in cardiac myocytes. Simulations reveal that as a result of network interactions, reduction in the level of one PDE is partially compensated for by increased activation of others. PDE2 and PDE4 exert the strongest compensatory roles among all PDEs. In addition, PDE2 competes with other PDEs to bind and hydrolyze cAMP and is a strong regulator of PDE interactions. Finally, an increasing level of cGMP gradually out-competes cAMP for the catalytic sites of PDEs 1, 2, and 3, suppresses their cAMP hydrolysis rates, and results in amplified cAMP signaling. These results provide insights into how PDEs transduce cGMP signals to regulate cAMP and how PDE interactions affect cardiac β-adrenergic response.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiac myocytes; Computational model; Cyclic nucleotides; Phosphodiesterase; Signaling networks; β-adrenergic pathway

Mesh:

Substances:

Year:  2015        PMID: 26388264      PMCID: PMC4641241          DOI: 10.1016/j.yjmcc.2015.09.011

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  86 in total

Review 1.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 2.  Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions.

Authors:  Sharron H Francis; Mitsi A Blount; Jackie D Corbin
Journal:  Physiol Rev       Date:  2011-04       Impact factor: 37.312

Review 3.  PDEs create local domains of cAMP signaling.

Authors:  Delphine Mika; Jérôme Leroy; Grégoire Vandecasteele; Rodolphe Fischmeister
Journal:  J Mol Cell Cardiol       Date:  2011-08-23       Impact factor: 5.000

Review 4.  AKAPs: the architectural underpinnings of local cAMP signaling.

Authors:  Michael D Kritzer; Jinliang Li; Kimberly Dodge-Kafka; Michael S Kapiloff
Journal:  J Mol Cell Cardiol       Date:  2011-05-11       Impact factor: 5.000

5.  Local control of β-adrenergic stimulation: Effects on ventricular myocyte electrophysiology and Ca(2+)-transient.

Authors:  Jordi Heijman; Paul G A Volders; Ronald L Westra; Yoram Rudy
Journal:  J Mol Cell Cardiol       Date:  2011-02-21       Impact factor: 5.000

Review 6.  Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.

Authors:  Clint L Miller; Chen Yan
Journal:  J Cardiovasc Transl Res       Date:  2010-07-15       Impact factor: 4.132

7.  Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals.

Authors:  Aniella Abi-Gerges; Wito Richter; Florence Lefebvre; Philippe Mateo; Audrey Varin; Christophe Heymes; Jane-Lise Samuel; Claire Lugnier; Marco Conti; Rodolphe Fischmeister; Grégoire Vandecasteele
Journal:  Circ Res       Date:  2009-09-10       Impact factor: 17.367

Review 8.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.

Authors:  Emily J Tsai; David A Kass
Journal:  Pharmacol Ther       Date:  2009-03-21       Impact factor: 12.310

9.  Modeling cardiac β-adrenergic signaling with normalized-Hill differential equations: comparison with a biochemical model.

Authors:  Matthew J Kraeutler; Anthony R Soltis; Jeffrey J Saucerman
Journal:  BMC Syst Biol       Date:  2010-11-18

10.  Conserved expression and functions of PDE4 in rodent and human heart.

Authors:  Wito Richter; Moses Xie; Colleen Scheitrum; Judith Krall; Matthew A Movsesian; Marco Conti
Journal:  Basic Res Cardiol       Date:  2010-12-16       Impact factor: 17.165

View more
  12 in total

1.  Cross-regulation of Phosphodiesterase 1 and Phosphodiesterase 2 Activities Controls Dopamine-mediated Striatal α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Trafficking.

Authors:  Roy S Song; Rosa Tolentino; Eric A Sobie; Susana R Neves-Zaph
Journal:  J Biol Chem       Date:  2016-09-07       Impact factor: 5.157

2.  Mechanisms of the cyclic nucleotide cross-talk signaling network in cardiac L-type calcium channel regulation.

Authors:  Claire Y Zhao; Joseph L Greenstein; Raimond L Winslow
Journal:  J Mol Cell Cardiol       Date:  2017-03-29       Impact factor: 5.000

Review 3.  Insulin and β Adrenergic Receptor Signaling: Crosstalk in Heart.

Authors:  Qin Fu; Qingtong Wang; Yang K Xiang
Journal:  Trends Endocrinol Metab       Date:  2017-02-28       Impact factor: 12.015

Review 4.  Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.

Authors:  Rima Kamel; Jérôme Leroy; Grégoire Vandecasteele; Rodolphe Fischmeister
Journal:  Nat Rev Cardiol       Date:  2022-09-01       Impact factor: 49.421

5.  Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network.

Authors:  Claire Y Zhao; Joseph L Greenstein; Raimond L Winslow
Journal:  J Mol Cell Cardiol       Date:  2016-01-07       Impact factor: 5.000

6.  Treatment of Cardiovascular Dysfunction With PDE5-Inhibitors - Temperature Dependent Effects on Transport and Metabolism of cAMP and cGMP.

Authors:  Anders L Selli; Adrina K Kuzmiszyn; Natalia Smaglyukova; Timofei V Kondratiev; Ole-Martin Fuskevåg; Roy A Lyså; Aina W Ravna; Torkjel Tveita; Georg Sager; Erik S Dietrichs
Journal:  Front Physiol       Date:  2021-07-30       Impact factor: 4.566

7.  Mathematical Modelling of Nitric Oxide/Cyclic GMP/Cyclic AMP Signalling in Platelets.

Authors:  Rune Kleppe; Inge Jonassen; Stein Ove Døskeland; Frode Selheim
Journal:  Int J Mol Sci       Date:  2018-02-19       Impact factor: 5.923

Review 8.  Imaging of PDE2- and PDE3-Mediated cGMP-to-cAMP Cross-Talk in Cardiomyocytes.

Authors:  Nikoleta Pavlaki; Viacheslav O Nikolaev
Journal:  J Cardiovasc Dev Dis       Date:  2018-01-19

9.  Phosphodiesterase 5 Associates With β2 Adrenergic Receptor to Modulate Cardiac Function in Type 2 Diabetic Hearts.

Authors:  Toni M West; Qingtong Wang; Bingqing Deng; Yu Zhang; Federica Barbagallo; Gopireddy R Reddy; Dana Chen; Kyle S Phan; Bing Xu; Andres Isidori; Yang K Xiang
Journal:  J Am Heart Assoc       Date:  2019-07-17       Impact factor: 5.501

Review 10.  PDE4-Mediated cAMP Signalling.

Authors:  Bracy A Fertig; George S Baillie
Journal:  J Cardiovasc Dev Dis       Date:  2018-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.